Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.44 |
| ▸ | NPC1 | O15118 | 8/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 2/20 | 0.42 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.42 |
| ▸ | SRC | P12931 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.40 |
| ▸ | DDX3X | O00571 | 3/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | PTGES | O14684 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4950581 | 0.81 | NPC1 (0.40) | RAB9ANPC1ALDH1A1LMNARXFP1 | |
| SCHEMBL18584726 | 0.75 | BCAT2 (0.61) | RAB9ANPC1RXFP1SMN1; SMN2ROCK2 | |
| SCHEMBL7873448 | 0.73 | MAPT (0.48) | RAB9ANPC1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL4949867 | 0.72 | GSTO1 (0.49) | RAB9ANPC1ALDH1A1LMNARXFP1 | |
| SCHEMBL4949391 | 0.70 | SIRT2 (0.35) | RAB9ANPC1ALDH1A1MEN1KMT2A | |
| SCHEMBL1965022 | 0.69 | BCAT2 (0.44) | RAB9ANPC1RXFP1ROCK2MEN1 | |
| SCHEMBL1968944 | 0.68 | BCAT2 (0.43) | RAB9ANPC1RXFP1KDM4EROCK2 | |
| SCHEMBL4945042 | 0.68 | SIRT2 (0.40) | RAB9ANPC1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL4951232 | 0.67 | ATAD2 (0.49) | RAB9ANPC1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL4945624 | 0.67 | FSCN1 (0.50) | RAB9ANPC1ALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080076741-A1 | ENHANCEMENT OF TIGECYCLINE POTENCY USING EFFLUX PUMP INHIBITORS | REMPEX PHARMACEUTICALS, INC. | 2008-03-27 | — | — | US | disclosed |
| EP-1758920-A1 | BACTERIAL EFFLUX PUMP INHIBITORS AND METHODS OF TREATING BACTERIAL INFECTIONS | MPEX PHARMACEUTICALS, INC. (US) | 2007-03-07 | — | — | EP | disclosed |
| US-20060003944-A1 | Bacterial efflux pump inhibitors and methods of treating bacterial infections | REMPEX PHARMACEUTICALS, INC. | 2006-01-05 | — | — | US | disclosed |
| WO-2005113579-A1 | BACTERIAL EFFLUX PUMP INHIBITORS AND METHODS OF TREATING BACTERIAL INFECTIONS | MPEX PHARMACEUTICALS, INC. (US) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076741-A1 | ENHANCEMENT OF TIGECYCLINE POTENCY USING EFFLUX PUMP INHIBITORS | ABCB1, ABCB11, SLC47A2 | RAB9A 534/4885NPC1 503/4885ALDH1A1 3712/4885 |
| US-20060003944-A1 | Bacterial efflux pump inhibitors and methods of treating bacterial infections | ABCB11, ABCB1, ABCC1 | RAB9A 463/4885NPC1 97/4885ALDH1A1 2512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.